Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl

The d- and l-versions of the Bcr-Abl SH2 domain (12.7 kDa) were synthesized. Key optimizations included pseudoproline incorporation, N-terminal hydrophilic tail addition and mild N-acetoxy succinimide acetylation. Their folding and activity are as for the recombinant protein. Our results will enable...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Nina, Abendroth, Frank, Vázquez, Olalla, Hantschel, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347351/
https://www.ncbi.nlm.nih.gov/pubmed/35975004
http://dx.doi.org/10.1039/d2cb00108j
_version_ 1784761841259380736
author Schmidt, Nina
Abendroth, Frank
Vázquez, Olalla
Hantschel, Oliver
author_facet Schmidt, Nina
Abendroth, Frank
Vázquez, Olalla
Hantschel, Oliver
author_sort Schmidt, Nina
collection PubMed
description The d- and l-versions of the Bcr-Abl SH2 domain (12.7 kDa) were synthesized. Key optimizations included pseudoproline incorporation, N-terminal hydrophilic tail addition and mild N-acetoxy succinimide acetylation. Their folding and activity are as for the recombinant protein. Our results will enable engineering of mirror-image monobody antagonists of the central oncoprotein Bcr-Abl.
format Online
Article
Text
id pubmed-9347351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-93473512022-08-15 Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl Schmidt, Nina Abendroth, Frank Vázquez, Olalla Hantschel, Oliver RSC Chem Biol Chemistry The d- and l-versions of the Bcr-Abl SH2 domain (12.7 kDa) were synthesized. Key optimizations included pseudoproline incorporation, N-terminal hydrophilic tail addition and mild N-acetoxy succinimide acetylation. Their folding and activity are as for the recombinant protein. Our results will enable engineering of mirror-image monobody antagonists of the central oncoprotein Bcr-Abl. RSC 2022-07-06 /pmc/articles/PMC9347351/ /pubmed/35975004 http://dx.doi.org/10.1039/d2cb00108j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Schmidt, Nina
Abendroth, Frank
Vázquez, Olalla
Hantschel, Oliver
Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title_full Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title_fullStr Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title_full_unstemmed Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title_short Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
title_sort synthesis of the l- and d-sh2 domain of the leukaemia oncogene bcr-abl
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347351/
https://www.ncbi.nlm.nih.gov/pubmed/35975004
http://dx.doi.org/10.1039/d2cb00108j
work_keys_str_mv AT schmidtnina synthesisofthelanddsh2domainoftheleukaemiaoncogenebcrabl
AT abendrothfrank synthesisofthelanddsh2domainoftheleukaemiaoncogenebcrabl
AT vazquezolalla synthesisofthelanddsh2domainoftheleukaemiaoncogenebcrabl
AT hantscheloliver synthesisofthelanddsh2domainoftheleukaemiaoncogenebcrabl

Ejemplares similares